Hepatic Encephalopathy in Children With Acute Liver Failure: Utility of Serum Neuromarkers

Pediatric Acute Liver Failure Study Group

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Pediatric acute liver failure (PALF) is a public heath burden, often requiring prolonged hospitalization and liver transplantation. Hepatic encephalopathy (HE) is a complication of PALF with limited diagnostic tools to predict outcomes. Serum neurological markers (neuron-specific enolase, S100β, and myelin basic protein) can be elevated in traumatic or ischemic brain injury. We hypothesized that these neuromarkers would be associated with the development of HE in PALF. METHODS: PALF study participants enrolled between May 2012 and December 2014 by 12 participating centers were the subjects of this analysis. Daily HE assessments were determined by study investigators. Neurological and inflammatory markers were measured using enzyme-linked immunosorbent assay and MILLIPLEX techniques, respectively. To model encephalopathy, these markers were log2 transformed and individually examined for association with HE using a generalized linear mixed model with a logit link and random intercept. RESULTS: Eighty-two children had neurological and inflammatory marker levels and HE assessments recorded, with the majority having assessments for 3 days during their illness. An indeterminate diagnosis (29%) was most common and the median age was 2.9 years. Significant associations were observed for HE with S100β (odds ratio 1.16, 95% confidence interval [1.03-1.29], P = 0.04) and IL-6 (odds ratio 1.24 [1.11-1.38], P = 0.006). CONCLUSIONS: Serum S100β and IL-6 are associated with HE in children with PALF. Measuring these markers may assist in assessing neurological injury in PALF, impacting clinical decisions.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalJournal of pediatric gastroenterology and nutrition
Volume69
Issue number1
DOIs
StatePublished - Jul 1 2019

Fingerprint

Hepatic Encephalopathy
Acute Liver Failure
Pediatrics
Serum
Interleukin-6
Odds Ratio
Myelin Basic Protein
Phosphopyruvate Hydratase
Brain Diseases
Liver Transplantation
Brain Injuries
Linear Models
Hospitalization
Biomarkers
Enzyme-Linked Immunosorbent Assay
Research Personnel
Confidence Intervals
Wounds and Injuries

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

Hepatic Encephalopathy in Children With Acute Liver Failure : Utility of Serum Neuromarkers. / Pediatric Acute Liver Failure Study Group.

In: Journal of pediatric gastroenterology and nutrition, Vol. 69, No. 1, 01.07.2019, p. 108-115.

Research output: Contribution to journalArticle

@article{3d0354d15bfc4c4eaf26fa6d85fbf8ec,
title = "Hepatic Encephalopathy in Children With Acute Liver Failure: Utility of Serum Neuromarkers",
abstract = "BACKGROUND: Pediatric acute liver failure (PALF) is a public heath burden, often requiring prolonged hospitalization and liver transplantation. Hepatic encephalopathy (HE) is a complication of PALF with limited diagnostic tools to predict outcomes. Serum neurological markers (neuron-specific enolase, S100β, and myelin basic protein) can be elevated in traumatic or ischemic brain injury. We hypothesized that these neuromarkers would be associated with the development of HE in PALF. METHODS: PALF study participants enrolled between May 2012 and December 2014 by 12 participating centers were the subjects of this analysis. Daily HE assessments were determined by study investigators. Neurological and inflammatory markers were measured using enzyme-linked immunosorbent assay and MILLIPLEX techniques, respectively. To model encephalopathy, these markers were log2 transformed and individually examined for association with HE using a generalized linear mixed model with a logit link and random intercept. RESULTS: Eighty-two children had neurological and inflammatory marker levels and HE assessments recorded, with the majority having assessments for 3 days during their illness. An indeterminate diagnosis (29{\%}) was most common and the median age was 2.9 years. Significant associations were observed for HE with S100β (odds ratio 1.16, 95{\%} confidence interval [1.03-1.29], P = 0.04) and IL-6 (odds ratio 1.24 [1.11-1.38], P = 0.006). CONCLUSIONS: Serum S100β and IL-6 are associated with HE in children with PALF. Measuring these markers may assist in assessing neurological injury in PALF, impacting clinical decisions.",
author = "{Pediatric Acute Liver Failure Study Group} and Toney, {Nicole A.} and Bell, {Michael J.} and Belle, {Steven H.} and Hardison, {Regina M.} and Norberto Rodriguez-Baez and Loomes, {Kathleen M.} and Yoram Vodovotz and Ruben Zamora and Squires, {Robert H.}",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/MPG.0000000000002351",
language = "English (US)",
volume = "69",
pages = "108--115",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hepatic Encephalopathy in Children With Acute Liver Failure

T2 - Utility of Serum Neuromarkers

AU - Pediatric Acute Liver Failure Study Group

AU - Toney, Nicole A.

AU - Bell, Michael J.

AU - Belle, Steven H.

AU - Hardison, Regina M.

AU - Rodriguez-Baez, Norberto

AU - Loomes, Kathleen M.

AU - Vodovotz, Yoram

AU - Zamora, Ruben

AU - Squires, Robert H.

PY - 2019/7/1

Y1 - 2019/7/1

N2 - BACKGROUND: Pediatric acute liver failure (PALF) is a public heath burden, often requiring prolonged hospitalization and liver transplantation. Hepatic encephalopathy (HE) is a complication of PALF with limited diagnostic tools to predict outcomes. Serum neurological markers (neuron-specific enolase, S100β, and myelin basic protein) can be elevated in traumatic or ischemic brain injury. We hypothesized that these neuromarkers would be associated with the development of HE in PALF. METHODS: PALF study participants enrolled between May 2012 and December 2014 by 12 participating centers were the subjects of this analysis. Daily HE assessments were determined by study investigators. Neurological and inflammatory markers were measured using enzyme-linked immunosorbent assay and MILLIPLEX techniques, respectively. To model encephalopathy, these markers were log2 transformed and individually examined for association with HE using a generalized linear mixed model with a logit link and random intercept. RESULTS: Eighty-two children had neurological and inflammatory marker levels and HE assessments recorded, with the majority having assessments for 3 days during their illness. An indeterminate diagnosis (29%) was most common and the median age was 2.9 years. Significant associations were observed for HE with S100β (odds ratio 1.16, 95% confidence interval [1.03-1.29], P = 0.04) and IL-6 (odds ratio 1.24 [1.11-1.38], P = 0.006). CONCLUSIONS: Serum S100β and IL-6 are associated with HE in children with PALF. Measuring these markers may assist in assessing neurological injury in PALF, impacting clinical decisions.

AB - BACKGROUND: Pediatric acute liver failure (PALF) is a public heath burden, often requiring prolonged hospitalization and liver transplantation. Hepatic encephalopathy (HE) is a complication of PALF with limited diagnostic tools to predict outcomes. Serum neurological markers (neuron-specific enolase, S100β, and myelin basic protein) can be elevated in traumatic or ischemic brain injury. We hypothesized that these neuromarkers would be associated with the development of HE in PALF. METHODS: PALF study participants enrolled between May 2012 and December 2014 by 12 participating centers were the subjects of this analysis. Daily HE assessments were determined by study investigators. Neurological and inflammatory markers were measured using enzyme-linked immunosorbent assay and MILLIPLEX techniques, respectively. To model encephalopathy, these markers were log2 transformed and individually examined for association with HE using a generalized linear mixed model with a logit link and random intercept. RESULTS: Eighty-two children had neurological and inflammatory marker levels and HE assessments recorded, with the majority having assessments for 3 days during their illness. An indeterminate diagnosis (29%) was most common and the median age was 2.9 years. Significant associations were observed for HE with S100β (odds ratio 1.16, 95% confidence interval [1.03-1.29], P = 0.04) and IL-6 (odds ratio 1.24 [1.11-1.38], P = 0.006). CONCLUSIONS: Serum S100β and IL-6 are associated with HE in children with PALF. Measuring these markers may assist in assessing neurological injury in PALF, impacting clinical decisions.

UR - http://www.scopus.com/inward/record.url?scp=85068587867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068587867&partnerID=8YFLogxK

U2 - 10.1097/MPG.0000000000002351

DO - 10.1097/MPG.0000000000002351

M3 - Article

C2 - 31058776

AN - SCOPUS:85068587867

VL - 69

SP - 108

EP - 115

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -